Article Sidebar

Submitted
2 October 2019
Accepted
2 October 2019
Published
3 October 2019
Download
PDF
Statistic
Read Counter : 1333 Download : 1539

Main Article Content

Abstract

Various tyrosine kinase inhibitor (TKI) drugs have been widely used as therapy for cancer that has EGFR mutations, or abnormal EGFR activation. However, patients who have a mutation in the gene that activates EGFR only benefit from EGFR-TKI therapy for less than one year, because after that resistance occurs. In the management of patients according to NCCN 2017, patients who experience progress after receiving TKI as the first-line therapy must undergo an examination to identify the presence of T790M mutation. If the T790M mutation is positive, the choice of therapy that needs to be provided is the third generation (Osimertinib). Many recent studies have proved the significance of the effectiveness and response of Osimertinib therapy in lung cancer with EGFR T790M mutation. We reported the management of a pulmonary adenocarcinoma patient with positive EGFR mutation who had received first-line EGFR TKI who had progressive disease and T790M mutation in Dr. Seotomo Hospital. The patient finally received Osimertinib through an Early Access Program with a therapeutic response that improved significantly.

Keywords

Tyrosine kinase inhibitor TKI resistance T790M mutation progressive disease osimertinib

Article Details

License

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Sahrun, S., & Wulandari, L. (2019). Case report: Management of Progressive Lung Cancer Patients after First-Line EGFR Tyrosine Kinase Inhibitor Therapy. Folia Medica Indonesiana, 55(3), 239–245. https://doi.org/10.20473/fmi.v55i3.15509
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Arief N (2009). Kegawatdaruratan paru, departemen pulmonologi dan ilmu kedokteran respirasi FKUI RS PERSAHABATAN, Universitas Indonesia
  2. Blom JW, Doggen CJ, Osanto S, et al (2005). Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293, 715-722. Available from https://www.ncbi.nlm.nih. gov/pubmed/157019 13. Accessed September 13, 2018
  3. Brzezniak C, Oronsky B, Carter CA, et al (2017). Superior vena cava syndrome in a patient with small-cell lung cancer: A case report. Case Rep Oncol 10, p 252-257
  4. Carson JL, Kelley MA, Duff A, et al (1992). The clinical course of pulmonary embolism. N Engl J Med 326, p 1240-1245. Available from https://www.ncbi .nlm.nih.gov/pubmed/ 1560799. Accessed September 11, 2018
  5. Ciardiello F, Tortora G (2008). EGFR Antagonists in Cancer Treatment. N Engl J Med 358, 1160-1174
  6. David SE, Douglas EW, Dara LA, et al (2017). Non-Small Cell Lung Cancer, Version 5, Clinical Practice Guidelines in Oncology. J National Comprehensive Cancer Network (NCCN) 15, 504-535
  7. Ettinger DS, Akerley W, Bepler G, et al (2010). Non - small cell lung cancer clinical practice guidelines in oncology. Natl Compr Cancer Netw 8, 740-801
  8. Falanga A (2009). The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. Cancer Investig 27, 105-115. Available from https://www.ncbi.nlm.nih.gov/ pubmed/19160098. Accessed September 14, 2018
  9. Greene FL, Page DL, Fleming ID, et al (2002). Cancer Survival Analysis. In: AJJ Cancer Staging handbook, 6th Ed. New York, Springer, p 15-25
  10. Huang L, Fu L (2015). Mechanisms of recistance to EGFR tyrosine kinase inhibitors. Acta Pharmaceutica Sinica B 5, 390-401. Available from https://core.ac. uk/download/pdf/ 82702660.pdf. Accessed September 12, 2018
  11. Jemal A, Bray F, Center MM, et al (2003). Global cancer statistics. A Cancer Journal Clinicians 61, 69-90
  12. Kosasih, Alvin, Susanto AD, et al (2008). Diagnosis Dan Tatalaksana Kegawatdaruratan Paru Dalam Praktek Sehari-hari, Jakarta, Sagung Seto
  13. Lee AY (2005). Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol 128, p 291-302. Available from https://www.ncbi.nlm.nih.gov/ pubmed/ 15667530. Accessed 09 10, 2018
  14. Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatinpaclitaxel in pulmonary Adenokarsinoma. N Engl J Med 361, p 947-57
  15. Nordstrom M, Lindblad B, Bergqvist D, et al (1992). A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 232(2), p 155-160. Availabe from https://www.ncbi.nlm.nih.gov/pubmed/1506812. Accessed 09 14, 2018
  16. Parkin DM, Bray F, Ferlay J, et al (2002). Global cancer statistics 2002. A Cancer Journal Clinicians 55(2), p 74-108
  17. Rosell R, Moran T, Queralt C, et al (2009). Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361, 958-67
  18. Sequist LV, Waltman BA, Dias-Santagata D, et al (2011). Genotypic and histological evolution of lung cancers acquiring recistance to EGFR inhibitors. Sci Transl Med 3, 75ra26
  19. Shinagare AB, Guo M, Hatabu H, et al (2011). Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center. Cancer 117, p 3860-6. Available from https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3131455/. Accessed September 11, 2018
  20. Socinski MA, Villaruz LC, Ross J (2016). Understanding mechanisms of recistance in the epithelial growth factor receptor in non-small cell lung cancer and the role of biopsy at progression. Oncologist 21, 1-9
  21. Sorensen HT, Mellemkjaer L, Olsen JH, et al (2000). Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343, 1846-50. Available from https://www.ncbi. nlm.nih.gov/pub-med/11117976. Accessed September 13, 2018
  22. Thomas A, D'Amico MD, Malcolm M, et al (2004). EGF receptor gene mutation are common in lung cancer from "never smokers” and are associated with sensitivity of tumors to gefinitib and erlotinib.Proceedings of the National Academy of Science 101, 13306-11
  23. WHO (2004). Histological of the tumor of the lung. In: Tumor of the lung-WHO classification
  24. Yang P, Cerhan JR, Vierkan RA, et al (2002). Adenokarsinoma of the lung is strongly associated with cigarette smoking: further evidence from a prospective study of women. American Journal of Epidemiology 156, 1114-1122
  25. Yun C, Mengwasser KE, Toms A V, et al (2008). The T790M mutation in EGFR kinase causes drug recistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105, 2070-2075. Available from https://www.ncbi.nlm.nih.gov/pubmed/18227510. Accessed September 11, 2018